Key result
Beta-blockers for rate control appear to confer benefits in critically ill patients with new-onset atrial fibrillation, while the advantage of anticoagulation remains ambiguous due to bleeding risks.
Why the study?
New-onset atrial fibrillation is the most prevalent arrhythmia in critically ill patients and correlates with heightened morbidity and mortality, but current management evidence is limited.
Design
Review
Authors
Loading...
Limited evidence for NOAF management in critically ill patients; leaves open optimal rate/rhythm/anticoagulation strategies pending dedicated RCTs.
Beta-blockers are preferred for rate control in critically ill patients with new-onset atrial fibrillation, while anticoagulation requires individualized risk-benefit assessment due to bleeding risks.
Wang et al. (2024) conducted a review in New-onset atrial fibrillation (NOAF) in critical illness. Atrial fibrillation treatments (rate or rhythm control, anticoagulation) was evaluated. Beta-blockers for rate control appear to confer benefits in critically ill patients with new-onset atrial fibrillation, while the advantage of anticoagulation remains ambiguous due to bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: